Immunotherapy Archives

microbiome seres eligo flagship cancer evelo

News and Trends 17 Nov 2015

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

The Microbiome and Immuno-Oncology fields are hugely trendy in the Biotech Industry – and now a marriage between the two has finally occurred… The Microbiome field is still very new, with the launch of the US Human Microbiome Project just happening in 2008. Nonetheless, some start-ups are moving fast up the microbiome ranks, as well […]

November 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Nov 2015

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cell-based Immune-oncology therapies continue to deliver amazing results. After Cellectis wondersaving from last week, Oxford’s Adaptimmune has some surprisingly good results too. Adaptimmune is a British, Oxford-based immuno-oncolgy company. It held a massive IPO last year, raising up to €150M on the NASDAQ, and its CEO was interviewed by BIO (video here) where he seemed […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

peter Llewellyn Davies medigene interview

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star. Medigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts […]

November 3, 2015 - 1 minutemin - By Philip Hemme

interview simon moroney labiotech bio europe

News and Trends 2 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

BIO-Europe is also a great opportunity to meet with top people from EU’s Biotech ecosystem. I had the chance to interview Simon Moroney, the CEO and one of the founders of MorphoSys (part of our top 9 EU-based billion euros Biotechs). The Munich-based company was founded in 1992 and now counts +-350 employees for a market […]

November 2, 2015 - 1 minutemin - By Philip Hemme

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment. Affimed Therapeutics is a NASDAQ-listed biotech […]

October 19, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Oct 2015

Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

This week, we’re leaving Paris and heading East to a city that’s 9 times bigger than the capital of France, it’s also the city we all call home here at Labiotech, Berlin. When someone thinks of Berlin, they think of the wall, the Fernsehturm (television tower) and its amazing nightlife (I can personally agree with this 😉 […]

October 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Oct 2015

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

Merck has opted to return its Phenylketonuria (PKU) candidates Kuvan and Peg-Pal back to BioMarin from January 2016. Merck will instead focus on other R&D areas, and will receive €340M in compensation (5 times the annual sales of Kuvan) with €180M for future Peg-Pal milestones. This appears to support the back-peddling trend of major Biotechs […]

October 2, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us